Treatment of Advanced Stage Hodgkin’s Disease

Hodgkin’s disease remains one of the few malignant diseases which can be cured by modern chemotherapy in most cases even in advanced stages. Adriamycin-containing chemotherapy regimens are considered as the standard therapy which induce long-term remission in about 60–70% of patients. The ABVD scheme, developed by Bonadonna and colleagues in Milan, has a favorable toxicity profile and causes less myelotoxicity, acute leukemia or sterility relative to many previous treatment programs containing alkylating agents. However, 20– 30 % of patients eventually relapse and are then frequently treated with high-dose programs including stem cell transplantation. There are two major goals in advanced Hodgkin’s disease: (1) to improve the cure rate and (2) to reduce acute and long-term toxicities. The recent definition of prognostic factors identified patients who are at a high risk of treatment failure as well as those in whom less toxic approaches can be applied. The optimal approach or program has not yet been defined, although new chemotherapy regimens such as BEACOPP and Stanford V with increased tumor response rates have been identified. These new drug combinations are currently analyzed and compared with ABVD in several international trials. While the addition of radiotherapy improved disease control in some trials a survival benefit was not identified and the role of radiotherapy remains controversial. High dose programs remain experimental in advanced stage Hodgkin’s disease and should be restricted to prospective clinical trials.

[1]  Olker,et al.  A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .

[2]  H Tesch,et al.  BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[4]  V. Diehl,et al.  Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Goldstone The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  V. Diehl,et al.  BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Horning,et al.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.

[8]  J. Raemaekers,et al.  Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Bonadonna,et al.  Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Reece,et al.  Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1996, Leukemia & lymphoma.

[11]  V. Diehl,et al.  Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Horning,et al.  Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Pfreundschuh,et al.  Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease , 1995 .

[14]  V. Diehl,et al.  Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  V. Diehl,et al.  Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). , 1995, Leukemia & lymphoma.

[16]  T. Miller,et al.  Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.

[17]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Chopra,et al.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.

[19]  V. Diehl Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). , 1993, Annals of hematology.

[20]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[21]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1992, Leukemia & lymphoma.

[22]  A. Bacigalupo,et al.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.

[23]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1991, European journal of cancer.

[24]  B. Clarkson,et al.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Flavio Crippa,et al.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Hancock Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[29]  G. Rosner,et al.  BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. , 1984, Annals of internal medicine.

[30]  G E Hanks,et al.  Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals , 1983, Cancer.

[31]  C. Coltman,et al.  Comparison of adriamycin‐containing chemotherapy (MOP‐BAP) with MOPP‐bleomycin in the management of advanced Hodgkin‐s disease a southwest oncology group study , 1983, Cancer.

[32]  S. Rosenberg,et al.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Schmoll Review of etoposide single-agent activity. , 1982, Cancer treatment reviews.

[34]  V. Devita,et al.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. , 1980, Annals of internal medicine.

[35]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[36]  T. Pajak,et al.  A comparative study of a bcnu containing 4‐drug program versus mopp versus 3‐drug combinations in advanced Hodgkin's disease. A cooperative study by the cancer and leukemia group B , 1979, Cancer.

[37]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[38]  T. Lister,et al.  MVPP chemotherapy regimen for advanced Hodgkin's disease , 1978, British medical journal.

[39]  F. Wilner,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.

[40]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[41]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.

[42]  A. Stansfeld,et al.  Combination Chemotherapy in Generalized Hodgkin's Disease , 1970, British medical journal.

[43]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[44]  John McGrath,et al.  Hodgkin’s Disease , 1933, JAMA.